Clinical improvement after treatment with VEGF(165) in patients with severe chronic lower limb ischaemia.

IF 3.5 Q1 EDUCATION & EDUCATIONAL RESEARCH
Genomic medicine Pub Date : 2007-01-01 Epub Date: 2007-05-25 DOI:10.1007/s11568-007-9006-5
Andrei Anghel, Bogdan Mut-Vitcu, Lorand Savu, Catalin Marian, Edward Seclaman, Raluca Iman, Adriana-Maria Neghina, Stefan I Dragulescu
{"title":"Clinical improvement after treatment with VEGF(165) in patients with severe chronic lower limb ischaemia.","authors":"Andrei Anghel,&nbsp;Bogdan Mut-Vitcu,&nbsp;Lorand Savu,&nbsp;Catalin Marian,&nbsp;Edward Seclaman,&nbsp;Raluca Iman,&nbsp;Adriana-Maria Neghina,&nbsp;Stefan I Dragulescu","doi":"10.1007/s11568-007-9006-5","DOIUrl":null,"url":null,"abstract":"<p><p>The present study focuses on the application of a therapeutic strategy in patients with chronic severe lower limb ischaemia using a plasmid vector encoding the vascular endothelial growth factor (phVEGF(165)). It has been shown that VEGF promotes neo-vascularization and blood vessel network formation and thus might have the ability to improve blood-flow at the level of the affected limbs. However, little information is available regarding the necessary level of expression of VEGF and its possible related adverse effects. We have subcloned VEGF ( 165 )isoform into pCMV-Script expression vector (Stratagene) under the control of the CMV promoter. Three patients with chronic ischaemia of the lower limb, considered as not suitable for surgical re-vascularization, received intramuscular injection with 0.5 ml saline solution containing 10(11) copies of VEGF ( 165 ) plasmid. The clinical evolution has been monitored by angiography and estimated by walking time on the rolling carpet (Gardner protocol). Two months after therapy, all three patients showed complete relief of rest pain, improvement of ischaemic ulcer lesions and increased walking distance on the rolling carpet most probably due to appearance of newly formed collateral vessels.</p>","PeriodicalId":87975,"journal":{"name":"Genomic medicine","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11568-007-9006-5","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genomic medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11568-007-9006-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2007/5/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"EDUCATION & EDUCATIONAL RESEARCH","Score":null,"Total":0}
引用次数: 13

Abstract

The present study focuses on the application of a therapeutic strategy in patients with chronic severe lower limb ischaemia using a plasmid vector encoding the vascular endothelial growth factor (phVEGF(165)). It has been shown that VEGF promotes neo-vascularization and blood vessel network formation and thus might have the ability to improve blood-flow at the level of the affected limbs. However, little information is available regarding the necessary level of expression of VEGF and its possible related adverse effects. We have subcloned VEGF ( 165 )isoform into pCMV-Script expression vector (Stratagene) under the control of the CMV promoter. Three patients with chronic ischaemia of the lower limb, considered as not suitable for surgical re-vascularization, received intramuscular injection with 0.5 ml saline solution containing 10(11) copies of VEGF ( 165 ) plasmid. The clinical evolution has been monitored by angiography and estimated by walking time on the rolling carpet (Gardner protocol). Two months after therapy, all three patients showed complete relief of rest pain, improvement of ischaemic ulcer lesions and increased walking distance on the rolling carpet most probably due to appearance of newly formed collateral vessels.

Abstract Image

Abstract Image

Abstract Image

VEGF治疗严重慢性下肢缺血后的临床改善(165)。
目前的研究重点是使用编码血管内皮生长因子(phVEGF)的质粒载体在慢性严重下肢缺血患者中的治疗策略的应用。研究表明,VEGF促进新血管形成和血管网络的形成,因此可能有能力改善患肢水平的血流量。然而,关于VEGF表达的必要水平及其可能的相关不良反应的信息很少。我们在CMV启动子的控制下,将VEGF(165)亚型亚克隆到pCMV-Script表达载体(Stratagene)中。3例下肢慢性缺血患者,认为不适合手术血管重建,肌内注射含有10(11)拷贝VEGF(165)质粒的生理盐水溶液0.5 ml。通过血管造影监测临床进展,并通过在滚动地毯上行走时间进行评估(Gardner方案)。治疗2个月后,3例患者休息疼痛完全缓解,缺血性溃疡病变改善,在滚动地毯上行走距离增加,这很可能是由于新形成的侧支血管的出现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信